Glucokinase – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)- Pipeline Review, H2 2019’, provides in depth analysis on Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Metabolic Disorders under development targeting Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

– The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Eli Lilly and Co

Hua Medicine Shanghai Ltd

Ligand Pharmaceuticals Inc

Merck & Co Inc

Pfizer Inc

Sanwa Kagaku Kenkyusho Co Ltd

Teijin Pharma Ltd

vTv Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Overview

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Companies Involved in Therapeutics Development

Amgen Inc

Eli Lilly and Co

Ligand Pharmaceuticals Inc

Merck & Co Inc

Poxel SA

Sanwa Kagaku Kenkyusho Co Ltd

Teijin Pharma Ltd

vTv Therapeutics Inc

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Drug Profiles

AM-9514 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dorzagliatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2608204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMG-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTP-399 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Dormant Products

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Discontinued Products

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Product Development Milestones

Featured News & Press Releases

Jun 22, 2018: vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions

Mar 22, 2018: vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes

Nov 08, 2017: vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes

Oct 17, 2016: Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug

Aug 10, 2016: vTv Therapeutics Announces Positive Topline Results From Phase 2B Study Of Glucokinase Activator TTP399 In Type 2 Diabetes

Jun 14, 2016: vTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions

Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity

Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes

Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial

Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective Glucokinase Activator, for the Treatment of Type 2 Diabetes

Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug

Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control

Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics

Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients

Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by Hua Medicine Shanghai Ltd, H2 2019

Pipeline by Ligand Pharmaceuticals Inc, H2 2019

Pipeline by Merck & Co Inc, H2 2019

Pipeline by Pfizer Inc, H2 2019

Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019

Pipeline by Teijin Pharma Ltd, H2 2019

Pipeline by vTv Therapeutics Inc, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports